TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

被引：34
|
作者：
Yi, Ming [1 ,2 ]
Li, Tianye [3 ]
Niu, Mengke [1 ]
Wu, Yuze [1 ]
Zhao, Zhenyu [4 ]
Wu, Kongming [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Breast Surg, Hangzhou, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Gynecol, Hangzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Urol, Tongji Med Coll,Dept Urol, Wuhan, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金：
中国博士后科学基金; 中国国家自然科学基金;
关键词：
cancer biotherapy; cancer immunotherapy; tumor microenvironment; TGF-beta; PD-1; PD-L1; bispecific antibody; NONSMALL CELL LUNG; SMALL-MOLECULE INHIBITOR; SODIUM LY573636 SODIUM; MONOCLONAL-ANTIBODY; BELAGENPUMATUCEL-L; TASISULAM SODIUM; PD-1; BLOCKADE; BREAST-CANCER; LY2157299; MONOHYDRATE; ANTITUMOR-ACTIVITY;
D O I：
10.3389/fimmu.2022.1061394
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Transforming growth factor-beta (TGF-beta) signaling regulates multiple physiological processes, such as cell proliferation, differentiation, immune homeostasis, and wound healing. Besides, TGF-beta plays a vital role in diseases, including cancer. Accumulating evidence indicates that TGF-beta controls the composition and behavior of immune components in the tumor microenvironment (TME). Advanced cancers leverage TGF-beta to reshape the TME and escape immune surveillance. TGF-beta-mediated immune evasion is an unfavorable factor for cancer immunotherapy, especially immune checkpoint inhibitors (ICI). Numerous preclinical and clinical studies have demonstrated that hyperactive TGF-beta signaling is closely associated with ICI resistance. It has been validated that TGF-beta blockade synergizes with ICI and overcomes treatment resistance. TGF-beta-targeted therapies, including trap and bispecific antibodies, have shown immense potential for cancer immunotherapy. In this review, we summarized the predictive value of TGF-beta signaling and the prospects of TGF-beta-targeted therapies for cancer immunotherapy.
引用
收藏
页数：12
相关论文
共 50 条
  • [41] Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
    Gang Chen
    Alexander C. Huang
    Wei Zhang
    Gao Zhang
    Min Wu
    Wei Xu
    Zili Yu
    Jiegang Yang
    Beike Wang
    Honghong Sun
    Houfu Xia
    Qiwen Man
    Wenqun Zhong
    Leonardo F. Antelo
    Bin Wu
    Xuepeng Xiong
    Xiaoming Liu
    Lei Guan
    Ting Li
    Shujing Liu
    Ruifeng Yang
    Youtao Lu
    Liyun Dong
    Suzanne McGettigan
    Rajasekharan Somasundaram
    Ravi Radhakrishnan
    Gordon Mills
    Yiling Lu
    Junhyong Kim
    Youhai H. Chen
    Haidong Dong
    Yifang Zhao
    Giorgos C. Karakousis
    Tara C. Mitchell
    Lynn M. Schuchter
    Meenhard Herlyn
    E. John Wherry
    Xiaowei Xu
    Wei Guo
    [J]. Nature, 2018, 560 : 382 - 386
  • [42] Identification of novel antagonistic anti-PD-1 antibodies that are non-blocking of the PD-1/PD-L1 interaction
    Fenwick, Craig
    Pellaton, Celine
    Farina, Alex
    Radja, Navina
    Pantaleo, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
    Katy K. Tsai
    Adil I. Daud
    [J]. Drugs, 2015, 75 : 563 - 575
  • [44] The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
    Tsai, Katy K.
    Daud, Adil I.
    [J]. DRUGS, 2015, 75 (06) : 563 - 575
  • [45] Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies?
    Matias, M.
    Aspeslagh, S.
    Palomar, V.
    Lanoy, E.
    Dercle, L.
    Even, C.
    Ferte, C.
    Hollebecque, A.
    Marabelle, A.
    Massard, C.
    Soria, J-C.
    Postel-Vinay, S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [46] Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
    Kudo, Masatoshi
    [J]. LIVER CANCER, 2020, 9 (06) : 629 - 639
  • [47] Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies
    Liu, Shufang
    Niu, Wenquan
    [J]. JAMA ONCOLOGY, 2020, 6 (02) : 298 - 299
  • [48] Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
    Sibaud, Vincent
    Meyer, Nicolas
    Lamant, Laurence
    Vigarios, Emmanuelle
    Mazieres, Julien
    Delord, Jean Pierre
    [J]. CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) : 254 - 263
  • [49] Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
    Chen, Gang
    Huang, Alexander C.
    Zhang, Wei
    Zhang, Gao
    Wu, Min
    Xu, Wei
    Yu, Zili
    Yang, Jiegang
    Wang, Beike
    Sun, Honghong
    Xia, Houfu
    Man, Qiwen
    Zhong, Wenqun
    Antelo, Leonardo F.
    Wu, Bin
    Xiong, Xuepeng
    Liu, Xiaoming
    Guan, Lei
    Li, Ting
    Liu, Shujing
    Yang, Ruifeng
    Lu, Youtao
    Dong, Liyun
    McGettigan, Suzanne
    Somasundaram, Rajasekharan
    Radhakrishnan, Ravi
    Mills, Gordon
    Lu, Yiling
    Kim, Junhyong
    Chen, Youhai H.
    Dong, Haidong
    Zhao, Yifang
    Karakousis, Giorgos C.
    Mitchell, Tara C.
    Schuchter, Lynn M.
    Herlyn, Meenhard
    Wherry, E. John
    Xu, Xiaowei
    Guo, Wei
    [J]. NATURE, 2018, 560 (7718) : 382 - +
  • [50] Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma
    Patrinely, James R., Jr.
    Baker, Laura X.
    Davis, Elizabeth J.
    Song, Haocan
    Ye, Fei
    Johnson, Douglas B.
    [J]. CANCER, 2020, 126 (15) : 3448 - 3455
12345